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Matchmaking for the
Optimization of Clinical Trials
of Heart Failure With
Preserved Ejection Fraction
No Laughing Matter*
Sanjiv J. Shah, MD
Chicago, Illinois
Heart failure (HF) with preserved ejection fraction (HFpEF)
is common and associated with high morbidity and mor-
tality: HFpEF represents >50% of all HF, and it is growing
in prevalence (1); quality of life is generally poor, comparable
with that among patients with end-stage renal disease (2);
and 5-year survival is only 35% after HF hospitalization (3).
In addition, care of patients with HFpEF can be frustrating:
the diagnosis is often not straightforward; comorbidities are
common and drive outcomes in these patients (4,5); and
treatment of patients with HFpEF remains an enigma,
with disappointing results from several large randomized
controlled trials (6). Thus, it is not surprising that many
clinicians feel “therapeutic nihilism” toward HFpEF.
See page 1330
Why have prior clinical trials of HFpEF failed? There
are multiple possibilities (7), but for clinicians who care for
patients with HFpEF on a frequent basis, it is clear that
the heterogeneity of HFpEF is one primary reason (8).
HFpEF, like all forms of HF, is a syndrome, not a speciﬁc
disease process. The overwhelming majority of patients with
HFpEF have elevated left ventricular (LV) ﬁlling pressures,
either at rest or with exertion.However, the severity of the left
atrial pressure elevation, volume retention, and consequent
pulmonary hypertension with right ventricular dysfunction
is variable, as are the etiologic and pathophysiologic paths*Editorials published in the Journal of the American College of Cardiology reﬂect the
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size ﬁts all” treatment strategy is unlikely to work for patients
withHFpEF andmay underlie the failures of previous clinical
trials.
For future clinical trials of HFpEF to be successful, better
matching of therapies with the correct type of HFpEF
patient, and endpoints tested, is necessary. Sometimes only
in retrospect is it clear that the type of therapy tested in
a clinical trial may not be the right match for the types of
patients enrolled (or the outcomes tested). Recent examples
of this phenomenon include the ALDO-DHF (Aldosterone
Receptor Blockade in Diastolic Heart Failure) trial, which
enrolled patients with early-stage HFpEF and not overt
volume overload (9), and RELAX (Phosphodiesterase-5
Inhibition to Improve Clinical Status and Exercise
Capacity in Heart Failure With Preserved Ejection Frac-
tion) (10), which enrolled symptomatic patients with volume
overload but not necessarily those with overt pulmonary
hypertension and right ventricular dysfunction. However, in
other studies, the mechanism of the experimental drug is
well matched to the type of patients enrolled and the
endpoints tested.
In this issue of the Journal, Kosmala et al. (11) report their
results from just such a study: a short-term, randomized
controlled trial of the effects of ivabradine compared with
placebo on exercise capacity and hemodynamic status in
patients with HFpEF (11). In this small, double-blind
clinical trial of 61 patients with early-stage HFpEF and
New York Heart Association class II and III symptoms, the
investigators randomized study participants to 7 days of
ivabradine 5 mg twice daily (n¼ 30) or placebo (n¼ 31). All
study participants underwent cardiopulmonary exercise
testing and diastolic stress echocardiography at baseline and
on day 7. The coprimary endpoints were peak oxygen
consumption and peak exercise E/e0 ratio (a noninvasive
surrogate for LV ﬁlling pressure). The results of the trial were
impressive: patients randomized to ivabradine had improved
exercise capacity, increased peak oxygen consumption,
and reduced exercise-induced increases in E/e0. Although the
trial was only a short-term 7-day study, the safety and
tolerability of ivabradine were also remarkable, with no
associated adverse effects and no need for dose reductions or
study drug cessation because of bradycardia.
Why was the trial by Kosmala et al. (11) successful?
The primary reason may be the drug tested (ivabradine)
and its beneﬁcial effects in HFpEF. However, matching
the drug and its proposed mechanism of beneﬁt to the right
type of HFpEF patient cannot be overemphasized, as
shown by analyzing several recent clinical trials of HFpEF
(Table 1) (2,9–18). Figure 1 displays a theoretical schema
of 3 different HFpEF patient types: exercise-induced dia-
stolic dysfunction (i.e., exercise-induced rise in LV ﬁlling
pressure), chronic volume overload, and associated right
heart failure or pulmonary hypertension. Each type of
patient can be classiﬁed as having HFpEF; however, the
3 types of HFpEF may represent different stages of the
Table 1 Summary of Selected Recent or Pending Randomized Controlled Trials of Heart Failure With Preserved Ejection Fraction
First Author/Trial (Ref.#) Intervention HFpEF Patient Type* Primary Endpoint Trial Result
Trial “Matched”
for Rx?
Kosmala et al. (11) Ivabradine Exercise-induced DD Peak VO2, peak E/e0 ratio Positive Yes
CHAMPION (12) CardioMEMS sensor Volume overload HF hospitalization Positive Yes
Guazzi et al. (14) Sildenaﬁl Right heart failure/PH Pulmonary hemodynamic
status, RV performance, QoL
Positive Yes
Kitzman et al. (15) Exercise training Exercise-induced DD Peak VO2 Positive Yes
PARAMOUNT (16) LCZ696 (ARNI) Volume overload DNT-proBNP Positive Yes
TOPCAT (2) Spironolactone Volume overload CV death, aborted cardiac
arrest, or HF hospitalization
Pending Yesz
Aldo-DHF (9) Spironolactone Exercise-induced DD Peak VO2, DE/e0 Negativey Noz
ELANDD (13) Nebivolol Exercise-induced DD 6-min walk test Negative Nox
J-DHF (17) Carvedilol (low dose) Exercise-induced DD/
volume overload
Death or HF hospitalization Negative Nox
RAAM-PEF (18) Eplerenone Volume overload 6-min walk test Negative Noz
RELAX (10) Sildenaﬁl Volume overload Peak VO2 Negative No
*HFpEF patient types include exercise-induced DD (ambulatory patients with NYHA class II and III symptoms, grade I DD, and normal or near normal B-type natriuretic peptide levels), chronic volume overload
(NYHA class II to IV symptoms with history of HF hospitalization, elevated BNP, and/or left atrial enlargement), and associated right heart failure or PH (NYHA class III and IV symptoms with evidence of
pulmonary vascular disease and/or RV dysfunction). See Figure 1 for examples of each patient type. yAldo-DHF had coprimary endpoints and was negative for the peak VO2 endpoint but positive for the
DE/e0 endpoint. zPrior HF trials of mineralocorticoid receptor antagonists have shown that these drugs reduce volume overload and diminish symptoms, but they do not improve exercise capacity or
functional class. xGiven the vasodilating effects of nebivolol and carvedilol, ELANDD and J-DHF may have been better suited with the chronic volume overload type of patient with HF hospitalization as an
endpoint; J-DHF may have been positive had higher doses of carvedilol been used in the study.
Aldo-DHF ¼ Aldosterone Receptor Blockade in Diastolic Heart Failure; ARNI ¼ angiotensin receptor/neprilysin inhibitor; CHAMPION ¼ CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve
Outcomes in NYHA Class III Patients; CV ¼ cardiovascular; DD ¼ diastolic dysfunction; ELANDD ¼ Effect of Long-Term Administration of Nebivolol on Clinical Symptoms, Exercise Capacity and Left Ventricular
Function in Patients With Diastolic Dysfunction; HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection fraction; J-DHF ¼ Japanese Diastolic Heart Failure; NT-proBNP ¼ N-terminal pro–B-type
natriuretic peptide; PARAMOUNT ¼ Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction; PH ¼ pulmonary hypertension; QoL ¼ quality of life; RAAM-
PEF ¼ Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction; RELAX ¼ Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With
Preserved Ejection Fraction; RV ¼ right ventricular; Rx ¼ treatment; TOPCAT ¼ Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; VO2 ¼ oxygen consumption.
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the culmination of environment, diet, comorbidities, and
genetic susceptibility.
The trial by Kosmala et al. (11) speciﬁcally tested the ﬁrst
type of HFpEF, which is characterized primarily by exercise-
induced elevations in LV ﬁlling pressures. These patients
often do not have signiﬁcant signs of ﬂuid overload at rest
and typically have New York Heart Association functional
class II symptoms, normal or near normal natriuretic peptide
levels, and grade I diastolic dysfunction on resting echo-
cardiography. Many of these patients do not even require
maintenance diuretic therapy. However, with exercise, their
LV ﬁlling pressures (and left atrial pressures) rise signiﬁ-
cantly, resulting in exercise intolerance and dyspnea. These
patients are not likely to beneﬁt from either spironolactone
or phosphodiesterase-5 inhibition, as shown in recent clin-
ical trials (9,10). Instead, a drug with heart rate–lowering
and lusitropic effects may be more desirable. Ivabradine is
just such as drug.
Ivabradine is a highly selective blocker of inward “funny”
channels, which are central regulators of spontaneous depo-
larization in pacemaker cells (19). Thus, ivabradine selectively
decreases heart rate without having negative inotropic or
lusitropic effects, as can occur with beta-blockers. Further-
more, animal and human studies have shown that ivabradine
can decrease heart rate while improving stroke volume and
cardiac output. An elegant study, which used a novel HFpEF
animal model, the db/db (leptin-receptor deﬁcient) mouse,
found that heart rate lowering with ivabradine had several
beneﬁcial effects, including reduced effective arterial
elastance, increased aortic distensibility, and decreased LVend-systolic elastance (20). In addition, ivabradine accelerated
myocardial relaxation by increased phosphorylation of phos-
pholamban, reversing the SERCA2a inhibition that was
present in the db/db mouse. Improving the activity of SER-
CA2a has several beneﬁcial downstream effects, including
reduction of titin N2B isoform expression and lowering
myocardial collagen content (20). Thus, ivabradine may be
useful in the short term with its lusitropic and hemodynamic
effects, thereby alleviating symptoms and improving exercise
capacity, and it may also be useful in the long term, decreasing
myocardial stiffness and thereby preventing the development
of worsening HF (volume overload).
The study by Kosmala et al. (11) has several strengths,
including its use of detailed exercise and echocardiographic
testing, speciﬁc enrollment criteria (signs and symptoms
of HFpEF, evidence of diastolic dysfunction, exercise
capacity <80% of age-predicted and sex-predicted values,
and E/e0 ratio >13 at peak stress). The 7-day duration of the
trial could be viewed as a positive aspect, because it allowed
the rapid determination of the drug’s efﬁcacy in improving
exercise tolerance. Finally, as stated above, perhaps the
biggest strength of the study was the accurate “match-
making” between experimental therapy (ivabradine) and
patient type (early-stage HFpEF with primary symptoms of
exercise intolerance due to exercise-induced elevations in LV
ﬁlling pressure).
Several limitations of the study should also be considered.
First, the study was small and included only white partici-
pants. Thus, the study results may not be generalizable
to other HFpEF patient types and populations, and a larger
ivabradine trial must be performed in HFpEF before its
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Figure 1
Theoretical Schema of Heart Failure With Preserved Ejection Fraction Patient Types With Sample Patients, Risk Proﬁles,
and Matched Therapies
AR ¼ aortic regurgitation; ARNI ¼ angiotensin receptor/neprilysin inhibitor; BNP ¼ B-type natriuretic peptide; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery
disease; CKD ¼ chronic kidney disease; DD ¼ diastolic dysfunction; DM2 ¼ type 2 diabetes mellitus; DOE ¼ dyspnea on exertion; E/e0 ¼ ratio of early mitral inﬂow to early
mitral annular diastolic tissue velocity; HF ¼ heart failure; HTN ¼ hypertension; If ¼ inward “funny” channel; LAE ¼ left atrial enlargement; LVEF ¼ left ventricular ejection
fraction; MR ¼ mitral regurgitation; MRA ¼ mineralocorticoid receptor antagonist; NYHA ¼ New York Heart Association; PASP ¼ pulmonary artery systolic pressure; PDE5 ¼
phosphodiesterase-5; RV ¼ right ventricular; RVH ¼ right ventricular hypertrophy; SOB ¼ shortness of breath; s/p ¼ status post.
JACC Vol. 62, No. 15, 2013 Shah
October 8, 2013:1339–42 Optimization of HFpEF Clinical Trials
1341use can be advocated in clinical practice. Second, the strict
inclusion and exclusion criteria beneﬁted the trial by
enrolling only carefully selected patients; however, futurelarger scale clinical trials of ivabradine inHFpEFmust enroll
patients using a different strategy than the typical large
multicenter HFpEF trials (2), which often use elevated
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1342natriuretic peptides and/or prior HF hospitalization as key
inclusion criteria. Third, in HFpEF, heart rate lowering can
be problematic in: 1) patients who have advanced diastolic
dysfunction and stiff left ventricles (and relativelyﬁxed stroke
volumes), because of the dependence on heart rate to
augment cardiac output in these cases; and 2) patients who
have chronotropic incompetence, in whom heart rate
lowering could also exacerbate symptoms (21). Finally,
because of the small sample size of the trial, the subgroup
analyses presented by Kosmala et al. (11) are limited and thus
may have missed adverse effects in problematic patient
populations, such as those with lower baseline heart rates or
those with undiagnosed chronotropic incompetence.
What are the next steps for ivabradine in patients with
HFpEF? On the basis of the data shown in the study by
Kosmala et al. (11), a large-scale, longer duration clinical
trial of ivabradine should be conducted in patients with
HFpEF; however, as noted previously, the inclusion and
exclusion criteria should focus on patients with early-stage
HFpEF, in whom exercise intolerance is the key symptom
and in whom there is objective evidence of exercise-induced
increase in LV ﬁlling pressure. Elevated natriuretic peptide
levels and/or prior HF hospitalization should not be used as
entry criteria, because they may result in the selection of
patients with more advanced HFpEF, who are unlikely to
beneﬁt from ivabradine. Finally, the primary endpoints for
a large-scale clinical trial of ivabradine in HFpEF should be
exercise capacity and quality of life, with prevention of
worsening HF (i.e., HF hospitalization) as a secondary,
exploratory endpoint.
In conclusion, Kosmala et al. (11) should be congratulated
for carrying out a carefully conducted and detailed exercise
hemodynamic study in patients with HFpEF. By taking
ivabradine, a blocker of the inward “funny” current, and
matching it with the right type of HFpEF patient, coupled
with appropriate endpoints (peak oxygen consumption and
exercise E/e0 ratio), the investigators were successful
matchmakers and may have found a novel therapy for an
otherwise difﬁcult-to-manage patient population.
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